Heteroarylakanoic acids as intergrin receptor antagonists
申请人:——
公开号:US20040092497A1
公开(公告)日:2004-05-13
The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr;
3
and/or the &agr;&ngr;&bgr;
5
integrin without significantly antagonizing the IIb/IIIa integrin.
1
This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine.
This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.
The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.
本发明提供了式(I)的化合物;其制药组合物,使用方法,制备方法或中间体。
Potentiators of Glutamate Receptors
申请人:Eli Lilly and Company
公开号:EP2441762A1
公开(公告)日:2012-04-18
The present invention provides compounds of formula I:
pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.
本发明提供了式 I 的化合物:
其药物组合物、使用方法、制备方法及其中间体。
HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS